yerba mate natural glp-1 Madre Organic Yerba Variety Pack yerbamate #yetbamaté #unimate #unimatefuel #glp

Phase 3 clinical trials are expected to conclude in May 2026, with potential FDA submissions in the US and MHRA submissions in the UK anticipated in 2026 or 2027

However, these tolerability issues ultimately impeded its regulatory and clinical progression

Importantly, these medications carry a boxed warning for risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), and are contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2

Triple Receptor Mechanism of Action Retatrutide's triple agonist mechanism operates across three complementary metabolic pathways